Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis : A European Multicenter Observational Study
Objective Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real‐life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. Methods We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015–2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ≤4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. Results Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty‐five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty‐two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty‐four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). Conclusion Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Arthritis & Rheumatology - 74(2022), 2, Seite 295-306 |
| BKL: |
|---|
| Anmerkungen: |
© 2022 American College of Rheumatology |
|---|
| Umfang: |
12 |
|---|
| doi: |
10.1002/art.41943 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY002441918 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY002441918 | ||
| 003 | DE-627 | ||
| 005 | 20230307115300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230211s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/art.41943 |2 doi | |
| 028 | 5 | 2 | |a ART_ART41943.xml |
| 035 | |a (DE-627)WLY002441918 | ||
| 035 | |a (WILEY)ART41943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.83 |2 bkl | ||
| 100 | 1 | |a Bettiol, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis |b A European Multicenter Observational Study |
| 264 | 1 | |c 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 American College of Rheumatology | ||
| 520 | |a Objective Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real‐life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. Methods We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015–2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ≤4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. Results Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty‐five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty‐two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty‐four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). Conclusion Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial. | ||
| 700 | 1 | |a Urban, Maria Letizia |4 aut | |
| 700 | 1 | |a Dagna, Lorenzo |4 aut | |
| 700 | 1 | |a Cottin, Vincent |4 aut | |
| 700 | 1 | |a Franceschini, Franco |4 aut | |
| 700 | 1 | |a Del Giacco, Stefano |4 aut | |
| 700 | 1 | |a Schiavon, Franco |4 aut | |
| 700 | 1 | |a Neumann, Thomas |4 aut | |
| 700 | 1 | |a Lopalco, Giuseppe |4 aut | |
| 700 | 1 | |a Novikov, Pavel |4 aut | |
| 700 | 1 | |a Baldini, Chiara |4 aut | |
| 700 | 1 | |a Lombardi, Carlo |4 aut | |
| 700 | 1 | |a Berti, Alvise |4 aut | |
| 700 | 1 | |a Alberici, Federico |4 aut | |
| 700 | 1 | |a Folci, Marco |4 aut | |
| 700 | 1 | |a Negrini, Simone |4 aut | |
| 700 | 1 | |a Sinico, Renato Alberto |4 aut | |
| 700 | 1 | |a Quartuccio, Luca |4 aut | |
| 700 | 1 | |a Lunardi, Claudio |4 aut | |
| 700 | 1 | |a Parronchi, Paola |4 aut | |
| 700 | 1 | |a Moosig, Frank |4 aut | |
| 700 | 1 | |a Espígol‐Frigolé, Georgina |4 aut | |
| 700 | 1 | |a Schroeder, Jan |4 aut | |
| 700 | 1 | |a Kernder, Anna Luise |4 aut | |
| 700 | 1 | |a Monti, Sara |4 aut | |
| 700 | 1 | |a Silvagni, Ettore |4 aut | |
| 700 | 1 | |a Crimi, Claudia |4 aut | |
| 700 | 1 | |a Cinetto, Francesco |4 aut | |
| 700 | 1 | |a Fraticelli, Paolo |4 aut | |
| 700 | 1 | |a Roccatello, Dario |4 aut | |
| 700 | 1 | |a Vacca, Angelo |4 aut | |
| 700 | 1 | |a Mohammad, Aladdin J. |4 aut | |
| 700 | 1 | |a Hellmich, Bernhard |4 aut | |
| 700 | 1 | |a Samson, Maxime |4 aut | |
| 700 | 1 | |a Bargagli, Elena |4 aut | |
| 700 | 1 | |a Cohen Tervaert, Jan Willem |4 aut | |
| 700 | 1 | |a Ribi, Camillo |4 aut | |
| 700 | 1 | |a Fiori, Davide |4 aut | |
| 700 | 1 | |a Bello, Federica |4 aut | |
| 700 | 1 | |a Fagni, Filippo |4 aut | |
| 700 | 1 | |a Moroni, Luca |4 aut | |
| 700 | 1 | |a Ramirez, Giuseppe Alvise |4 aut | |
| 700 | 1 | |a Nasser, Mouhamad |4 aut | |
| 700 | 1 | |a Marvisi, Chiara |4 aut | |
| 700 | 1 | |a Toniati, Paola |4 aut | |
| 700 | 1 | |a Firinu, Davide |4 aut | |
| 700 | 1 | |a Padoan, Roberto |4 aut | |
| 700 | 1 | |a Egan, Allyson |4 aut | |
| 700 | 1 | |a Seeliger, Benjamin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |4 aut | |
| 700 | 1 | |a Jayne, David |4 aut | |
| 700 | 1 | |a Prisco, Domenico |4 aut | |
| 700 | 1 | |a Vaglio, Augusto |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & Rheumatology |g 74(2022), 2, Seite 295-306 |w (DE-627)WLY002428598 |x 23265205 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:2 |g pages:295-306 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.83 |q ASE |
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 2 |h 295-306 |g 12 | ||